Efficacy and Safety of BIIB111 for the Treatment of Choroideremia
Completed · Phase 3
Conditions studied: Choroideremia
In brief
The objective of the study is to evaluate the efficacy and safety of a single sub-retinal injection of BIIB111 in participants with choroideremia (CHM).
Key facts
- Study ID
- NCT03496012
- Run by
- Biogen
- People needed
- 169
- Starts
- 2017-12-11
- Expected to finish
- 2020-12-01
- Last updated by the study team
- 2023-12-07
Who can join
Age: 18 and older. Sex: male. Healthy volunteers: not accepted.
Where it is running
- Research Site — Los Angeles, California, United States
- Research Site — Miami, Florida, United States
- Research Site — Baltimore, Maryland, United States
- Research Site — New York, New York, United States
- Research Site — Cincinnati, Ohio, United States
- Research Site — Portland, Oregon, United States
- Research Site — Dallas, Texas, United States
- Research Site — Madison, Wisconsin, United States
- Research Site — Montreal, Canada
- Research Site — Vancouver, Canada
- Research Site — Glostrup Municipality, Denmark
- Research Site — Helsinki, Finland
- Research Site — Montpellier, France
- Research Site — Bonn, Germany
- Research Site — Tübingen, Germany
- Research Site — Nijmegen, Netherlands
- Research Site — Manchester, United Kingdom
- Research Site — Oxford, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.